%20BIOSCIENCE%20CO.%2C%20LTD./other/MABWELL_SHANGHAI_BIOSCIENCE_CO._LTD.-logo.png){kind=logo}
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings
Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 迈威生物自愿披露关于9MW2821在2026年美国临床肿瘤学会（ASCO）以口头报告和壁报形式报告最新临床数据的公告 | 2026-05-21 | Chinese | |
| 迈威生物2026年第一季度报告 | 2026-04-28 | Chinese | |
| 迈威生物关于境外上市外资股（H股）公开发行价格的公告 | 2026-04-24 | Chinese | |
| 迈威生物关于2025年年度股东会增加会议地址的公告 | 2026-04-23 | Chinese | |
| 迈威生物关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告 | 2026-04-19 | Chinese | |
| 迈威生物自愿披露关于迈卫健?注射液增加适应症补充申请获得受理的公告 | 2026-04-15 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46757206 | 迈威生物自愿披露关于9MW2821在2026年美国临床肿瘤学会（ASCO）以口头报告和壁报形式报告最新临床数据的公告 | 2026-05-21 | Chinese | ||
| 44579773 | 迈威生物2026年第一季度报告 | 2026-04-28 | Chinese | ||
| 44579763 | 迈威生物关于境外上市外资股（H股）公开发行价格的公告 | 2026-04-24 | Chinese | ||
| 44579753 | 迈威生物关于2025年年度股东会增加会议地址的公告 | 2026-04-23 | Chinese | ||
| 44579751 | 迈威生物关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告 | 2026-04-19 | Chinese | ||
| 44579750 | 迈威生物自愿披露关于迈卫健?注射液增加适应症补充申请获得受理的公告 | 2026-04-15 | Chinese | ||
| 44579745 | 迈威生物自愿披露关于注射用6MW5311临床试验申请获得国家药品监督管理局受理的公告 | 2026-04-15 | Chinese | ||
| 44579742 | 迈威生物第二届董事会第三十次会议决议公告 | 2026-04-07 | Chinese | ||
| 44579731 | 公司章程（草案） | 2026-04-07 | Chinese | ||
| 44579717 | 董事会议事规则（草案） | 2026-04-07 | Chinese | ||
| 44579707 | 股东提名人选参选董事的程序（草案） | 2026-04-07 | Chinese | ||
| 44579699 | 董事会审计委员会工作细则（草案） | 2026-04-07 | Chinese | ||
| 44579685 | 对外担保管理制度（草案） | 2026-04-07 | Chinese | ||
| 44579678 | 独立董事工作制度（草案） | 2026-04-07 | Chinese | ||
| 44579669 | 董事会提名委员会工作细则》草案） | 2026-04-07 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
|
Adaptogenics Health Corp.
Formulates and distributes functional mushroom and adaptoge…
|
ADPT | CA | Manufacturing |
|
Adastra Holdings
Manufacturer and supplier of ethnobotanical and processed c…
|
XTRX | CA | Manufacturing |
|
ADBIOTECH Co.,Ltd.
Develops IgY-based immune antibodies as alternatives to vac…
|
179530 | KR | Manufacturing |
|
ADC Therapeutics SA
Commercial-stage biotech developing antibody-drug conjugate…
|
ADCT | US | Manufacturing |
|
Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators f…
|
ADXN | CH | Manufacturing |
|
Adeshwar Meditex Limited
Manufacturer and exporter of medical disposables, surgical …
|
543309 | IN | Manufacturing |
|
ADIAL PHARMACEUTICALS, INC.
A clinical-stage biopharma developing genetically targeted …
|
ADIL | US | Manufacturing |
|
Adicet Bio, Inc.
Develops allogeneic gamma delta T cell therapies for cancer…
|
ACET | US | Manufacturing |
|
ADIM
Develops and manufactures human vaccines and biologics for …
|
4142 | TW | Manufacturing |
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58111/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58111 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58111 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58111 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58111}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. (id: 58111)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.